95 related articles for article (PubMed ID: 35016)
1. Neuroleptic-potentiating effect of metyrosine.
Magelund G; Gerlach J; Casey DE
Am J Psychiatry; 1979 May; 136(5):732. PubMed ID: 35016
[No Abstract] [Full Text] [Related]
2. Neuroleptic-potentiating effect of alpha-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial.
Magelund G; Gerlach J; Casey DE
Acta Psychiatr Scand; 1979 Aug; 60(2):185-9. PubMed ID: 41413
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of dopamine synthesis in chronic schizophrenia. Clinical ineffectiveness of metyrosine.
Nasrallah HA; Donnelly EF; Bigelow LB; Rivera-Calimlim L; Rogol A; Potkin S; Rauscher FP; Wyatt RJ
Arch Gen Psychiatry; 1977 Jun; 34(6):649-55. PubMed ID: 17374
[TBL] [Abstract][Full Text] [Related]
4. Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique.
Wålinder J; Skott A; Carlsson A; Roos BE
Arch Gen Psychiatry; 1976 Apr; 33(4):501-5. PubMed ID: 779704
[TBL] [Abstract][Full Text] [Related]
5. The AMDP system in international clinical trials: a double-blind comparison of fluperlapine and haloperidol.
Woggon B; Linden M; Beckmann H; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pflug B; Schied HW
Psychopharmacol Bull; 1986; 22(1):47-51. PubMed ID: 2873619
[No Abstract] [Full Text] [Related]
6. Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial.
Fleischhacker WW; Barnas C; Stuppäck CH; Unterweger B; Miller C; Hinterhuber H
Psychopharmacol Bull; 1989; 25(1):97-100. PubMed ID: 2570438
[No Abstract] [Full Text] [Related]
7. Sulpiride--an antipsychotic agent: comparative trial vs. haloperidol.
Cassano GB; Castrogiovanni P; Conti L; Bonollo L
Psychopharmacol Bull; 1977 Jul; 13(3):41-3. PubMed ID: 18759
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double-blind, placebo-controlled trial.
Borison RL; Sinha D; Haverstock S; McLarnon MC; Diamond BI
Psychopharmacol Bull; 1989; 25(2):190-3. PubMed ID: 2574893
[No Abstract] [Full Text] [Related]
9. A comparison of the clinical effects of timiperone, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique.
Kariya T; Shimazono Y; Itoh H; Mori A; Murasaki M; Sugano K; Toru M; Yamashita I
J Int Med Res; 1983; 11(2):66-77. PubMed ID: 6133803
[TBL] [Abstract][Full Text] [Related]
10. Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia.
Silverstone T; Levine S; Freeman HL; Dubini A
Br J Psychiatry; 1984 Sep; 145():294-9. PubMed ID: 6148118
[TBL] [Abstract][Full Text] [Related]
11. [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():36-40. PubMed ID: 1683338
[TBL] [Abstract][Full Text] [Related]
12. [A randomized double-blinded controlled study on treatment of schizophrenia by in vitro fostered bezoar combined with haloperidol].
Weng SH; Wang GH; Wang XP
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Nov; 30(11):1213-5. PubMed ID: 21275180
[No Abstract] [Full Text] [Related]
13. Atypical antipsychotic drugs improve cognition in schizophrenia.
Meltzer HY; Sumiyoshi T
Biol Psychiatry; 2003 Feb; 53(3):265-7; author reply 267-8. PubMed ID: 12559661
[No Abstract] [Full Text] [Related]
14. Does a glutamate receptor blocker (Caroverine) enhance haloperidol in the treatment of schizophrenia?
König P; Conca A; Lugmayer B
Neuropsychobiology; 1999 Sep; 40(3):140-1. PubMed ID: 10494049
[No Abstract] [Full Text] [Related]
15. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.
Daniel DG; Wozniak P; Mack RJ; McCarthy BG
Psychopharmacol Bull; 1998; 34(1):61-9. PubMed ID: 9564200
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole: new drug. Just another neuroleptic.
Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
[TBL] [Abstract][Full Text] [Related]
17. The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study.
Zhang XY; Zhou DF; Cao LY; Wu GY; Shen YC
J Clin Psychopharmacol; 2006 Feb; 26(1):103-5. PubMed ID: 16415724
[No Abstract] [Full Text] [Related]
18. Propranolol in chronic schizophrenia: a controlled study in neuroleptic-treated patients.
Lindström LH; Persson E
Br J Psychiatry; 1980 Aug; 137():126-30. PubMed ID: 6107136
[TBL] [Abstract][Full Text] [Related]
19. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol.
den Boer JA; Westenberg HG
Psychopharmacol Bull; 1990; 26(1):99-107. PubMed ID: 1973547
[TBL] [Abstract][Full Text] [Related]
20. [The features of atypical neuroleptic amisulpride action].
Grigor'eva EA; Ritskov AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(6):59-64. PubMed ID: 15285638
[No Abstract] [Full Text] [Related]
[Next] [New Search]
